Squamous Cell Carcinoma And Immunosuppression Risks

Squamous Cell Carcinoma And Immunosuppression Risks Overview This study aimed to compare the clinical characteristics and outcomes of cutaneous squamous cell carcinoma (cSCC) in immunosuppressed and immunocompetent patients. The retrospective analysis included 935 cSCC cases, with 19.5% of the patients being immunosuppressed. The study revealed several notable findings: Immunosuppressed patients with

Acute Myeloid Leukemia And Diverse Patient Survival Outcomes

Acute Myeloid Leukemia And Diverse Patient Survival Outcomes Background Cancer remains a prominent global health concern, accounting for a significant number of cases and fatalities worldwide in 2020, with projections indicating further increases in both incidence and mortality rates, particularly in the United States. Hematologic malignancies (HMs) constitute a substantial subset of

Survival trends: pancreatic cancer in the USA

survival trends: pancreatic cancer in the USA STUDY BACKGROUND  Pancreatic cancer (PC) is a devastating malignancy with a 5-year survival rate of 10%. Despite accounting for only 3% of all new cancer diagnoses, it is the third leading cause of cancer-related deaths in the US. Surgical resection is the only potentially curative

Squamous Cell Carcinoma And Immunosuppression Risks